
==== Front
J Biol Chem
J Biol Chem
The Journal of Biological Chemistry
0021-9258
1083-351X
American Society for Biochemistry and Molecular Biology

S0021-9258(24)02210-5
10.1016/j.jbc.2024.107709
107709
JBC Reviews
O-GlcNAcylation in tumorigenesis and its implications for cancer therapy
Zhang Dize 12‡
Qi Yihang 3‡
Inuzuka Hiroyuki 3
Liu Jing jingliu@xjtu.edu.cn
12∗
Wei Wenyi wwei2@bidmc.harvard.edu
3∗
1 Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
2 Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
3 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
∗ For correspondence: Wenyi Wei; Jing Liu jingliu@xjtu.edu.cnwwei2@bidmc.harvard.edu
‡ These authors contributed equally to this work.

22 8 2024
9 2024
22 8 2024
300 9 10770920 6 2024
14 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a dynamic and reversible posttranslational modification that targets serine and threonine residues in a variety of proteins. Uridine diphospho-N-acetylglucosamine, which is synthesized from glucose via the hexosamine biosynthesis pathway, is the major donor of this modification. O-GlcNAc transferase is the sole enzyme that transfers GlcNAc onto protein substrates, while O-GlcNAcase is responsible for removing this modification. O-GlcNAcylation plays an important role in tumorigenesis and progression through the modification of specific protein substrates. In this review, we discuss the tumor-related biological functions of O-GlcNAcylation and summarize the recent progress in the development of pharmaceutical options to manipulate the O-GlcNAcylation of specific proteins as potential anticancer therapies.

Keywords

O-GlcNAcylation
tumorigenesis
cancer therapy
chemical-induced proximity
Abbreviations

AR androgen receptor

CIP chemical-induced proximity

CK2 casein kinase II

EZH2 enhancer of zeste homolog 2

FASN fatty acid synthase

GlcNAc N-acetylglucosamine

GLI2 GLI family zinc finger 2

HCC hepatocellular carcinoma

HIF-1a hypoxia-inducible factor-1a

LARS1 leucyl-tRNA synthetase 1

LATS large tumor suppressor kinase

LRP6 low density lipoprotein receptor related protein 6

MeCP2 methyl-CpG binding protein 2

mTORC1 mammalian target of rapamycin complex 1

OGA O-GlcNAcase

O-GlcNAcylation O-linked N-acetylglucosaminylation

OGT O-GlcNAc transferase

OGTAC O-GlcNAcylation targeting chimera

PDAC pancreatic ductal adenocarcinoma

PDK1 pyruvate dehydrogenase kinase 1

PD-L1 programmed death-ligand 1

PGK1 phosphoglycerate kinase 1

PKM2 pyruvate kinase M2

POI protein of interest

PPP pentose phosphate pathway

PROTAC proteolysis targeting chimera

PRPS1 phosphoribosyl pyrophosphate synthetase 1

PTM posttranslational protein modification

RACK1 receptor for activated C-kinase 1

RIPK3 receptor-interacting protein kinase 3

Shh sonic hedgehog

TME tumor microenvironment

Treg regulatory T

UDP-GlcNAc uridine diphospho-N-acetylglucosamine

ULK1 unc-51-like kinase 1

YAP yes-associated protein

Reviewed by members of the JBC Editorial Board. Edited by Robert Haltiwanger
==== Body
pmcO-GlcNAcylation is a type of posttranslational protein modification (PTM) that involves the addition of N-acetylglucosamine (GlcNAc) to the hydroxyl group of serine/threonine residues on target proteins (1). This process is dynamic and reversible and is controlled by two well-studied enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA, Fig. 1). OGT is responsible for transferring GlcNAc from Uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) to specific proteins for O-linked glycosylation (2), whereas OGA is responsible for removing this modification (3). The 14-3-3 proteins have been reported to be reader proteins of O-GlcNAcylation (4). UDP-GlcNAc, produced by the hexosamine biosynthesis pathway, is the main donor of O-GlcNAcylation, which can be influenced by a variety of upstream factors, such as glucose metabolism, insulin signaling, and the cellular stress response (5). O-GlcNAcylation plays a pivotal role in regulating a plethora of cellular functions, largely through the modification of specific substrate proteins, including transcription factors/cofactors (6), epigenetic regulators (7), protein kinases/phosphatases (8, 9, 10), and E3 ubiquitin ligases (11). Cancer cells usually have high OGT levels but low OGA expression levels, and elevated O-GlcNAcylation appears to be a general characteristic of cancer cells (12, 13, 14). To date, O-GlcNAcylation has been identified in thousands of proteins via low-throughput and high-throughput methods, as reviewed recently by others (5, 11, 15). Mechanistically, O-GlcNAcylation can occur on serine/threonine residues, which are critical phosphorylation sites, thus disrupting the phosphorylation-mediated regulation of protein substrates (16). In addition, O-GlcNAcylation might also protect proteins from ubiquitination-mediated protein degradation (17), providing another layer of regulation over protein turnover (Fig. 2).Figure 1 O-GlcNAcylation integrates multiple types of cellular metabolic signaling pathways into protein modifications. Glc: glucosamine, Glc-6-P: glucose-6-phosphate, Fruc-6P: fructose-6-phosphate, GlcN-6-P: glucosamine-6-phosphate, Acetyl-CoA: acetyl coenzyme A, GlcNAc-6-P: N-acetyl-D-glucosamine 6-phosphate, GlcNAc-1-P: N-acetyl-D-glucosamine 1-phosphate, UTP: uridine 5′-triphosphate, UDP-GlcNAc: uridine diphosphate N-acetylglucosamine OGT: O-GlcNAc transferase, OGA: O-GlcNAcase. O-GlcNAcylation, O-linked N-acetylglucosaminylation.

Figure 2 Upstream biological cues and downstream effects of protein O-GlcNAcylation. O-GlcNAcylation functions as a pivotal sensor for extracellular and intracellular cues and transduces these inputs onto diverse cell signaling pathways in part through the modification of different protein substrates, thus remodeling cellular functions, such as cell metabolism and cell signaling in the cytoplasm, as well as transcriptional regulation and chromosome remodeling in the nucleus. O-GlcNAcylation, O-linked N-acetylglucosaminylation.

Many efforts have been made to develop therapeutic options for cancer through the manipulation of the O-GlcNAcylation of proteins, primarily using specific inhibitors of OGT or OGA (15, 18). Recently, chemical-induced proximity (CIP) methods have been adopted to manipulate the PTMs of proteins, including ubiquitination, phosphorylation, acetylation, and O-GlcNAcylation, suggesting that this method is a powerful tool and potential therapeutic approach (19, 20). Although none of these CIPs has been approved by the Food and Drug Administration for clinical use, several proteolysis targeting chimeras (PROTACs) and molecular glue degraders have shown promising outcomes in early clinical trials (21, 22). Based on the current research progress on O-GlcNAcylation, in this review, we summarize the underlying mechanisms of O-GlcNAcylation in human cancer and summarize the current induction methods and mouse models of O-GlcNAcylation relevant to in vivo experiments. In addition, the achievements of biomedical engineering editing technology in the development of inhibitors that target O-GlcNAcylation are listed.

O-GlcNAcylation regulates cancer cell metabolism

Cells respond to extracellular and intracellular cues through diverse signaling pathways, and those signals are usually dysregulated in cancer cells. O-GlcNAcylation is sensitive to nutrients, hormones, and stress, thus enabling cells to reshape their metabolism and fate to adapt to these environmental inputs. Given that glucose is the major source of UDP-GlcNAc production, the disruption of glucose uptake and metabolism affects global intracellular O-GlcNAcylation levels. For example, glucose starvation increases the O-GlcNAcylation of leucyl-tRNA synthetase 1 (LARS1) at Ser-1042, which reduces the affinity of LARS1 for leucine by promoting unc-51-like kinase 1 (ULK1)-mediated LARS1 phosphorylation at the leucine-binding site, thus integrating glucose and amino acid metabolism (23). Compared with normal cells, cancer cells have a different metabolic homeostasis and prefer glycolysis rather than oxidative phosphorylation, termed the Warburg effect, and the O-GlcNAcylation of proteins is also not the same as that in normal cells.

O-GlcNAcylation has a dominant effect on cancer metabolism; for example, OGT inhibition reduces glucose uptake and lactate production, thus suppressing the proliferation of prostate cancer cells (24). Many enzymes involved in glycolysis and the pentose phosphate pathway (PPP) have been reported to undergo O-GlcNAcylation, serving as another layer regulating cancer metabolism (Fig. 3). Phosphofructokinase 1 (PFK1) is the first enzyme that commits glucose to glycolysis and catalyzes the irreversible conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. O-GlcNAcylation of Ser-529 of PFK1 in response to hypoxia inhibits its enzymatic activity and rewires cancer cell metabolism to the PPP, which represents a potential therapeutic option to target cancer metabolism (25). Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of the PPP, and hypoxia triggers its O-GlcNAcylation at Ser-84 in human lung cancers, leading to G6PD activation and metabolic flux into the PPP to produce intermediates of nucleotide and lipid biosynthesis in cancer cells (26). Phosphoglycerate kinase 1 (PGK1), a glycolytic enzyme that reversibly converts 1,3-diphosphoglycerate to 3-phosphoglycerate, can also be GlcNAcylated (27). Mechanistically, the O-GlcNAcylation of PGK1 at Thr-255 not only increases PGK1 kinase activity to increase lactate production but also triggers the translocation of PGK1 into mitochondria to phosphorylate and inhibit pyruvate dehydrogenase in colon cancer cells. Furthermore, blocking O-GlcNAcylation via the PGK1-T255V mutation inhibits colon cancer cell proliferation in vitro and retards tumor growth in vivo (27). Pyruvate kinase M2 (PKM2), an isoform specifically expressed in cancer cells, serves as a key driver of the Warburg effect. The O-GlcNAcylation levels of PKM2 at Thr-405 and Ser-406 are increased in both cancer cells and patient tumors (28), which leads to the destabilization of the active PKM2 tetramer and the nuclear translocation of PKM2 to enhance the Warburg effect, while blocking this O-GlcNAcylation attenuates tumor growth in vivo (28). Moreover, GlcNAcylation can be antagonized by ULK1-mediated PKM2 phosphorylation at Ser-333 (29). In addition to the abovementioned examples, many other metabolic enzymes in the tricarboxylic acid cycle are also substrates of O-GlcNAcylation, among which fumarate hydratase (FH) is O-GlcNAcylated at the Ser-75 residue, the same site as AMPK-mediated phosphorylation, and the O-GlcNAcylation of this site maintains tumor growth under glucose deficiency in pancreatic cancer patients (30).Figure 3 O-GlcNAcylation regulates cancer cell metabolism. O-GlcNAcylation occurs on multiple enzymes involved in the metabolism of glucose, lipids, and amino acids, thus reshaping cellular metabolism to promote cancer. G: O-GlcNAcylation. P: phosphorylation. O-GlcNAcylation, O-linked N-acetylglucosaminylation.

Lipid metabolism has attracted increasing attention in recent decades, and recent studies have revealed that several enzymes involved in lipid metabolism, such as fatty acid synthase (FASN), are O-GlcNAcylated. FASN is the sole enzyme for endogenous long-chain fatty acid synthesis and the rate-limiting enzyme of de novo lipogenesis. O-GlcNAcylation of FASN enhances its activity, thus protecting cancer cells from starvation, and dual inhibition of O-GlcNAcylation and FASN synergistically induces cancer cell death (31). In addition to directly modifying metabolic enzymes, O-GlcNAcylation can also regulate cellular metabolism through transcriptional, posttranscriptional, and posttranslational mechanisms. For example, serine/arginine-rich protein kinase 2 (SRPK2), a kinase for pre-mRNA splicing factors, can be O-GlcNAcylated at its nuclear localization signal to facilitate its import into the nucleus to phosphorylate pre-mRNA splicing factors, thus promoting the pre-mRNA splicing of lipogenic genes (32). Moreover, OGT regulates lipogenesis by indirectly increasing cyclin-dependent kinase 5-mediated Ser-267 phosphorylation of acetyl-CoA synthetase 2 (ACSS2) in glioblastoma cells (33).

Recent studies focusing on cancer metabolism have revealed a tumor type-specific metabolic vulnerability, such as glutamine and methionine metabolism (34). Pancreatic ductal adenocarcinomas (PDACs) rely on glutamine to sustain proliferation, and malate dehydrogenase 1 (MDH1), a key enzyme in glutamine metabolism, is highly O-GlcNAcylated at Ser-189 in PDAC patients, which enhances MDH1 enzymatic activity and glutamine metabolism, thus providing an Achilles heel for the treatment of PDAC (35). Furthermore, O-GlcNAcylation also functions in regulating nucleotide metabolism by modifying phosphoribosyl pyrophosphate synthetase 1 (PRPS1), a key enzyme in de novo nucleotide synthesis, at the Ser-83 and Thr-166 sites. O-GlcNAcylation of PRPS1 triggers its hexamerization and inhibits AMPK-mediated PRPS1 phosphorylation, thus increasing its activity and promoting tumorigenesis in lung cancer (36). Notably, OGT-mediated O-GlcNAcylation promotes glucose metabolism in cancer, indicating the potential of OGT inhibitors to serve as novel anticancer treatments.

O-GlcNAcylation regulates cancer cell signaling

Cell signal transduction is another major effector of protein O-GlcNAcylation (Fig. 4). Upon glucose starvation, the AMPK‒mTOR‒autophagy signaling pathway is activated to reshape cellular metabolism to adapt to nutrient deprivation conditions. O-GlcNAcylation of Raptor at Thr-700 facilitates its interaction with Rag GTPases, thus promoting activation of mammalian target of rapamycin complex 1 (mTORC1) (37). However, a genome-wide CRISPR‒Cas9 screen revealed the major role of OGT in maintaining low mTOR activity and mitochondrial fitness, while OGT loss increases intracellular amino acid levels to promote the lysosomal translocation of mTOR subsequent mTORC1 activation (Fig. 4A) (38). This discrepancy implies the complexity of O-GlcNAcylation in cancer, highlighting the possible toxicity of O-GlcNAcylation-targeted therapy in clinical practice. On the other hand, mTOR can regulate protein O-GlcNAcylation in cancer cells through the stabilization of OGT (39, 40). AMPK can also phosphorylate OGT at Thr-444 to inhibit histone O-GlcNAcylation rather than to directly disturb the enzymatic activity of OGT (41, 42). In addition, AMPK phosphorylates glutamine fructose-6-phosphate amidotransferase at Ser-243 to reduce the UDP-GlcNac donor, thus inhibiting O-GlcNAcylation (43). On the other hand, the α and γ subunits of the AMPK kinase complex might also undergo O-GlcNAcylation, which possibly inhibits its kinase activity to impact various downstream pathways (Fig. 4B) (41).Figure 4 O-GlcNAcylation regulates various cancer cell signaling pathways. O-GlcNAcylation occurs on key mediators of multiple cellular signaling pathways, which activates or inactivates these proteins, thus disrupting these signaling pathways to promote tumorigenesis, progression, and metastasis. These signaling pathways include but are not limited to the AMPK‒mTOR pathway (A), the AMPK‒HBP‒OGT pathway (B), the PI3K‒Akt pathway (C), the Hippo‒YAP pathway (D), the Wnt pathway (E), and the NF‒κB inflammatory pathway (F). G: O-GlcNAcylation. P: phosphorylation. HBP, hexosamine biosynthesis pathway; mTOR, mammalian target of rapamycin complex 1; OGT, O-GlcNAc transferase; O-GlcNAcylation, O-linked N-acetylglucosaminylation.

Hormones, especially insulin and glucagon, modulate O-GlcNAc signaling to remodel metabolic homeostasis in multiple tissues, such as the liver and fat. In response to insulin, OGT is tyrosine phosphorylated (44) and translocates from the nucleus to the cytoplasm, where it binds to phosphatidylinositol 3,4,5-trisphosphate and catalyzes O-GlcNAcylation of insulin signaling pathway proteins, such as insulin receptor substrate 1/2 (IRS1/2), phosphoinositide 3-kinase (PI3K), and pyruvate dehydrogenase kinase 1 (PDK1), thus suppressing insulin signal transduction (Fig. 4C) (44, 45). Upon glucagon stimulation, calcium/calmodulin-dependent kinase II (CaMKII) phosphorylates OGT and promotes the O-GlcNAc modification of ULK1, indicating an essential role for OGT in glucagon-stimulated autophagy, which is supported by the fact that genetic depletion of OGT reduces hepatic autophagy (46).

Elevated O-GlcNAcylation causes yes-associated protein (YAP) hyperactivation in cancer cells, and several proteins in the Hippo pathway, such as low density lipoprotein receptor related protein 6 (LRP6), large tumor suppressor kinase 2 (LATS2), and YAP, undergo O-GlcNAcylation, which eventually activates the Hippo pathway. O-GlcNAcylation of LRP6 is essential for its interaction with Merlin, and starvation reduces the O-GlcNAcylation and lysosomal degradation of LRP6, thus allowing Merlin to interact with LATS1/2 and inactivate YAP (47). O-GlcNAcylation of LATS2 occurs at the Thr-436 residue, which disrupts its interaction with MST-MOB1, thus leading to YAP hyperactivation in breast cancer cells (Fig. 4D) (48). YAP, the effector of the Hippo pathway that shuttles between the cytoplasm and nucleus in response to LATS-mediated phosphorylation, also undergoes O-GlcNAcylation at Thr-241 (49). This modification leads to YAP stabilization and the activation of the Hippo pathway, which is essential for high-glucose-induced liver tumorigenesis (49). Multiple regulatory proteins in the Hippo pathway are subjected to regulation by O-GlcNAcylation, and these modifications promote the maintenance of the oncogenic role of the Hippo pathway, suggesting the potential of O-GlcNAcylation as an alternative therapeutic choice to target the Hippo pathway in cancer.

β-Catenin, a pivotal factor in the Wnt signaling pathway, is GlcNAcylated at the Thr-41 residue, which protects it from ubiquitination-mediated degradation in colorectal cancer (50). Cell migration-inducing and hyaluronan-binding protein, an adaptor protein of OGT, binds to β-catenin and promotes its O-GlcNAcylation, thus increasing its nuclear translocation and subsequent transcription of glutamine metabolic enzymes, such as glutaminase 1 and glutamine transporters (SLC1A5 and SLC38A2), in colorectal cancer cells (51). These studies highlight the critical role of O-GlcNAcylation in the regulation of the Wnt signaling pathway, which warrants further in-depth studies (Fig. 4E).

O-GlcNAcylation also regulates the inflammatory pathway. Viral infection enhances hexosamine biosynthesis pathway (HBP) activity and protein O-GlcNAcylation, and genetic ablation of OGT causes defective antiviral immune responses (52). Mitochondrial antiviral signaling protein, the effector protein in the RNA-sensing antiviral pathway, can be O-GlcNAcylated at Ser-366, which is essential for the K63-linked ubiquitination of mitochondrial antiviral signaling protein and subsequent activation (52). However, another study reported that lipopolysaccharide stimulation leads to attenuated HBP activity and global O-GlcNAcylation levels, and ablation of OGT causes innate immune activation and exacerbates septic inflammation, indicating an anti-inflammatory effect of O-GlcNAcylation (8). In lipopolysaccharide-challenged macrophages, receptor-interacting protein kinase 3 (RIPK3) is O-GlcNAcylated at Thr-467, which disrupts its oligomerization and the RIPK3-RIPK1 interaction and thus inhibits necroptosis signaling (8). PDAC has a high HBP flux and O-GlcNAcylation levels, possibly due to high OGT and low OGA expression (53). High glucose levels induce the O-GlcNAcylation of IKK β at Ser-733, thus preventing an inhibitory phosphorylation event at the same site and enhancing NF-κB activity in cancer cells (Fig. 4F) (54). The p65 subunit of NF-κB is O-GlcNAcylated at Ser-550 and 551 upon NF-κB activation in PDAC (55), and promotes lung metastasis by activating C-X-C chemokine receptor type 4 (CXCR4) expressions in cervical cancer cells (56).

O-GlcNAcylation regulates transcription and translation in tumors

In addition to the direct modification of metabolic enzymes to remodel cancer cell metabolism, O-GlcNAcylation also occurs on the transcriptional regulatory machinery and epigenetic regulatory proteins, such as histones, transcription factors, and coactivators (Fig. 5). First, O-GlcNAcylation can directly affect DNA methylation by modifying DNA methyltransferase 1 (DNMT1) at its Ser-878 residue, which inhibits the methyltransferase activity of DNMT1 and eventually increases DNA damage and apoptosis (57). Second, histone H2B is GlcNAcylated at Ser-112, providing an anchor for a histone H2B ubiquitin ligase to promote its monoubiquitylation at Lys-120 (58). This GlcNAcylation is widely distributed across chromosomes and colocalizes with Lys-120 monoubiquitination to serve as a transcriptional activation code (58). In addition, GlcNAcylation also occurs on histone H2A at Ser-40 to maintain genome integrity (59, 60). O-GlcNAcylation at Ser-75 of enhancer of zeste homolog 2 (EZH2), which is the enzymatic subunit of the polycomb repressive complex 2 histone methyltransferase, increases its stability and hence facilitates H3K27me3-mediated gene silencing (61). In PDAC, O-GlcNAcylation occurs at Ser-136 of SIRT7, which protects it from degradation, while high expression of SIRT7 leads to hypoacetylation of H3K18 and the subsequent suppression of the transcription of tumor suppressor genes (62). Third, O-GlcNAcylation also regulates DNA topology in part by modifying DNA topoisomerase IIα (TOP2A) at Ser-1469, which enhances its chromatin DNA binding and catalytic activity, leading to resistance to chemotherapy in breast cancer (63). Finally, OGT is recruited to the histone deacetylase complex at promoters, where the transcription corepressor mSin3A targets it to modify and inactivate transcription factors and RNA polymerase II (RNAPII) (64). For example, O-GlcNAcylation of RNAPII on its C-terminal domain controls transcription initiation (65).Figure 5 O-GlcNAcylation regulates transcription and translation in cancer cells. O-GlcNAcylation occurs on key proteins involved in chromatin organization, transcription mechanisms, and epigenetic regulation, thus reprogramming an oncogenic transcription network to promote cancer. G: O-GlcNAcylation. O-GlcNAcylation, O-linked N-acetylglucosaminylation; PI3K, phosphoinositide 3-kinase.

The most important transcription factors regulating glycolysis enzymes, such as hypoxia-inducible factor-1α (HIF-1α), p53, and c-Myc, have been reported to be associated with O-GlcNAcylation, all of which promote glycolysis in cancer cells through the transcription of diverse glycolytic enzymes and glucose transporters. Myc is one of the earliest reported substrates of O-GlcNAcylation (66), which occurs on Thr-58, the same site of glycogen synthase kinase-mediated phosphorylation that plays a critical role in mediating its ubiquitination by the F-box/WD repeat-containing protein 7 (FBW7) E3 ligase and subsequent degradation by the 26S proteasome (67). In pancreatic cancer, O-GlcNAcylation of c-Myc not only increases the stability of c-Myc but also promotes the transcription of its downstream genes, such as programmed death-ligand 1 (PD-L1) (68). O-GlcNAcylation of HIF-1α promotes GLUT1 transcription, whereas suppression of O-GlcNAcylation leads to the hydroxylation of HIF-1α and its subsequent proteasomal degradation in human basal-like breast cancers (69). O-GlcNAcylation of p53 at Ser-149 is inversely correlated with its phosphorylation at Thr-155, the COP9 signalosome recognition site of p53. Thus, O-GlcNAcylation of p53 protects it from ubiquitin-dependent proteolysis (70). On the other hand, high glucose levels induce the O-GlcNAcylation of casein kinase II (CK2) and impede CK2-mediated phosphorylation of casein 2, thus releasing Cullin-4 (CRL4) to assemble the CRL4/COP1 E3 ligase complex that degrades p53 (71). Sterol regulatory element-binding transcription factor 1 is the master lipogenic transcription factor, and OGT regulates its protein abundance via AMPK (72). O-GlcNAcylation of another transcription factor, SP1, increases sterol regulatory element-binding transcription factor 1 (SREBP1) expression and lipid synthesis in liver and breast cancer cells (73). O-GlcNAcylation at Thr-114 of the TATA-box binding protein blocks its interaction with B-TFIID TATA-box binding protein associated factor 1 (BTAF1) and hence the formation of the B-TFIID complex, leading to gross alterations in lipid storage (74).

Many cancer driver transcription factors also undergo O-GlcNAcylation. In prostate cancer, O-GlcNAcylation occurs on the androgen receptor (AR) protein at the Thr-80 residue next to the Ser-81 phosphorylation site, which leads to stabilization, nuclear translocation, and transactivation of AR (75). Forkhead box protein A1 (FOXA1), a transcription factor involved in epigenetic reprogramming, is also O-GlcNAcylated at the Thr-432, Ser-441, and Ser-443 sites (76). These modifications reshape the interactome of FOXA1 to promote breast cancer metastasis by relocating it onto the chromatin loci of adhesion-related genes and simultaneously recruiting methyl-CpG binding protein 2 (MeCP2) to suppress the transcription of these genes (76). O-GlcNAcylation of the NF-κB subunit p65/RelA at Thr-305 and Ser-319 increases its acetylation at Lys-310 mediated by CREB-binding protein (CBP)/p300, and IKK-mediated phosphorylation at Ser-536, thus increasing its transcriptional activity in PDAC (53, 77).

In addition, O-GlcNAcylation also occurs on protein targets involved in mRNA regulation and protein translation, such as YTHDF1/3. YTHDF proteins are primary readers of N6-methyladenosine (m6A) modifications of mRNAs, which dictate that mRNAs undergo splicing, translation, or degradation. YTHDF1/3, rather than YTHDF2, has a high level of the O-GlcNAc modification, which suppresses YTHDF1/3-mediated translation-promoting functions (78). The translation initiation factors eIF4A and eIF4G are ATP-dependent RNA helicases that are crucial for the assembly of translationally active ribosomes. O-GlcNAcylation of eIF4A at Ser-322/323 disrupts the formation of the translation initiation machinery, suppressing protein synthesis and cell proliferation. On the other hand, O-GlcNAcylation of eIF4G at Ser-61 promotes its interaction with mRNA to induce protein synthesis and cell proliferation, indicating the complexity of translational control (79).

O-GlcNAcylation in the tumor microenvironment and the immune response

The tumor microenvironment refers to a complex and integrated system formed by the interactions of tumor cells with surrounding tissues, the extracellular matrix, blood vessels, and immune cells that plays a key role in tumor growth, metastasis, and the treatment response. O-GlcNAcylation participates in the regulation of the tumor microenvironment by modifying different substrate proteins. For example, hyaluronidase synthase 2 is a key component regulating the synthesis of hyaluronic acid in the extracellular matrix. O-GlcNAcylation of hyaluronidase synthase 2 at Ser-221 protects it from degradation, whereas a phosphorylation-mimic mutation of the same site reduces its stability, thus regulating hyaluronic acid production (80). O-GlcNAcylation also regulates tumor angiogenesis by modifying the corepressor Sp3, which further inhibits its recruitment to the promoter of angiopoietin-2 (Ang-2), thereby increasing Ang-2 expression and subsequently stimulating neovascularization in tumors (81). In prostate cancer, OGT ablation reduces the expression of angiogenic factors, such as vascular endothelial growth factor, matrix metallopeptidase 2 (MMP2), and MMP9, to block angiogenesis (82). In bladder cancer, O-GlcNAcylation promotes angiogenesis largely through the modification of Ser-101 in the seryl-tRNA synthetase (SerRS) protein, which promotes its degradation (83). Recently, immune checkpoints such as PD-L1 have been found to be subjected to O-GlcNAcylation, which protects against lysosomal degradation and promotes tumor immune evasion (84). In addition, O-GlcNAcylation is important for the development, transformation, and differentiation of T cells, whereas OGT loss compromises T-cell renewal and clonal expansion (85). T-cell-specific Ogt-null mice generated via CD4-Cre impair the differentiation and maturity of single-positive CD4+ or CD8+ T cells, although they have similar numbers of double-positive T cells (85). These studies highlight the potential of O-GlcNAcylation-targeted therapy for remodeling the tumor immune microenvironment and urge further in-depth investigations of its synergistic effect with immunotherapy.

Animal models for the study of O-GlcNAcylation

Various genetically modified mouse models have been developed to gain a more comprehensive understanding of the physiological functions of O-GlcNAc/OGT-related signaling pathways in vivo. The Ogt mRNA is expressed universally in all mouse tissues, and mice with global Ogt knockout (KO) (Ogt: X-linked gene, Ogt-/Y or Ogt−/−) exhibit embryonic lethality (86). Tamoxifen-inducible whole-body KO of Ogt results in lethality in adult mice, which underscores its crucial role in embryonic development and the survival of adult mice (87). UDP-GlcNAc serves as a substrate for OGT and a terminal metabolite of the HBP, which functions as a nutrition sensor. The connection between OGT and HBP has been established using genetically engineered mouse models. Transgenic mice overexpressing Ogt in muscle and fat display insulin resistance and elevated leptin levels (87). In contrast, muscle-specific Ogt KO in mice results in an increase in energy expenditure, accompanied by increased glucose uptake in both muscle and white adipose tissue (88). In addition, a study involving pancreatic β cell-specific Ogt KO mice demonstrated a substantial increase in blood glucose levels 2 months after initiating Ogt depletion, which was accompanied by increased β cell apoptosis (87). These findings highlight the critical role of OGT in nutritional sensing and glucose metabolism.

Considering the pivotal roles of the HBP in T-cell development and function, thymocyte-specific Ogt-KO mice were examined. The results showed that OGT plays a role in suppressing apoptosis in mature CD4+ and CD8+ single-positive thymocytes (89). Consistent with these findings, thymocyte-conditional Ogt KO mice, when bred with thymocyte-specific Pten KO mice, which serve as a mouse T-cell acute lymphoblastic leukemia (T-ALL) model, rescued the malignant phenotype of the Pten-null mice. This reversed phenotype is likely attributable to the impairment of positive selection in double-positive thymocytes and the suppression of T-cell clonal expansion, both of which are mediated by Ogt deletion (85). These findings indicate that OGT enzymatic activity likely plays a critical role in the development of T-cell malignancies, suggesting that OGT may be a potential target for treating T-cell leukemia.

Furthermore, multiple mouse models with conditional Ogt deletion have highlighted the essential role of OGT in regulating the immune system. In these models, the depletion of Ogt in B cells leads to increased apoptosis of mature B cells and impaired activation of B-cell receptor signaling, underscoring the essential role of OGT in maintaining B-cell homeostasis and immune responses (90). Mice with myeloid-specific Ogt deletion exhibit a decrease in cytokine expression induced by influenza A virus infection, highlighting the essential role of OGT in regulating antiviral responses (91). Furthermore, Ogt KO in regulatory T (Treg) cells is associated with increased systemic inflammation and the development of an autoimmune phenotype due to impaired Treg effector function (91).

The relationship between OGT enzymatic activity and cancer development was further investigated. To this end, Ser-355 in GLI family zinc finger 2 (GLI2) was found to be a crucial site for O-GlcNAcylation in the promotion of medulloblastoma. Medulloblastoma is a malignancy that affects the cerebellum in children and is caused by sustained Shh (sonic hedgehog) signaling in granule neuron precursors. GLI2, a transcription factor, plays a regulatory role in the sonic hedgehog (Shh) signaling pathway. OGT-mediated GLI2 O-GlcNAcylation impaired the interaction between GLI2 and p300, leading to increased GLI2 transcriptional activity and the promotion of medulloblastoma progression. Deletion of Ogt in granule neuron precursor suppressed tumor growth and increased the survival rate of a mouse model of medulloblastoma (92). This study proposed that OGT could be a viable therapeutic target for Shh-activated tumors. Furthermore, the pathological role of O-GlcNAcylation in hepatocellular carcinoma (HCC) has been reported in a ribosomal receptor for activated C-kinase 1 (RACK1) knock-in mouse model. O-GlcNAcylation of RACK1 at Ser-122 is essential for promoting HCC tumorigenesis and chemoresistance. Mechanistically, RACK1 serves as a scaffold protein for multiple signaling components, and its dysregulation is involved in several cancers. In an HCC mouse model, ablation of O-GlcNAcylation at Ser-122 of RACK1 by generating RACK1S122A/S122A knock-in mice significantly suppressed tumorigenesis, angiogenesis, and metastasis of HCC (93). Collectively, these mouse models provide critical insights into the development of potential therapeutic strategies that target OGT.

The physiological role of OGA in vivo has been extensively investigated in genetically engineered mouse models. Like Ogt, Oga is also widely expressed in mice. Oga homozygous whole-body KO leads to perinatal lethality due to delayed embryonic development. KO mice exhibit a smaller body size associated with delayed embryonic development and significantly reduced blood glucose and hepatic glycogen levels (94, 95). Consistent with this finding, the catalytically inactive Oga knock-in mouse (OGAD285A/D285A) displays neonatal lethality. OGA contains an N-terminal OGA catalytic domain and a C-terminal pseudohistone acetyltransferase domain. The lethality observed in knock-in mice suggests that the developmental defect in KO mice is largely attributable to the lack of OGA catalytic activity but is not mediated by the histone acetyltransferase domain (96). Furthermore, hematopoietic stem cell-specific KO of Oga in mice impaired the self-renewal of stem cells, diminished progenitor populations, and increased the degree of apoptosis in bone marrow cells. These findings highlight the crucial role of OGA in maintaining the homeostasis of hematopoietic stem cells. Furthermore, in terms of the relationship between OGA and cancer, research has shown that elevated levels of OGT, OGA, and O-GlcNAcylation are observed in colorectal cancer (97). Consistent with this result, heterozygous Oga KO in mice suppresses intestinal tumorigenesis on an adenomatous polyposis coli (Apc) mutant background and improves the survival rate of the mice (97). In light of the crucial role of O-GlcNAc cycling in cancer, additional in vivo analyses are necessary to assess the pathological implications of O-GlcNAcylation in cancer-related and O-GlcNAc cycling signaling pathways regulated by reciprocal OGT/OGA activities.

Therapeutic approaches to target O-GlcNAcylation in cancer

Multiple small-molecule inhibitors have been developed that either directly inhibit the activity of OGT or OGA or block key enzymes in the HBP to manipulate the O-GlcNAcylation of protein targets (Table 1, see details in other review (98)). These inhibitors include substrate analogs, transition state analogs, glutamine analogs, and others, among which several compounds are in clinical trials, such as Azaserine, DON, and DON precursor DRP-104 (15, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119). Moreover, streptozotocin, a Food and Drug Administration-approved drug for pancreatic neuroendocrine tumors, has also been suggested to be a transition state analog inhibitor of OGA.Table 1 Inhibitors that target the O-GlcNAcylation pathway in cancer

Target	Molecule	Mechanism of action	In vitro and in vivo effects	Ref.	
OGT	Alloxan	Uracil analog of UDP-GlcNAc	In vitro: weak inhibition of OGT with off-target effects
In vivo: ameliorates type 1 diabetes mellitus	(99, 100)	
OGT	BADGP	Analog of UDP-GlcNAc	In vitro: reduces O-GlcNAc level, but lacks specificity for OGT	(101)	
OGT	UDP-5SGlcNAc	5-thiosugar analog of UDP-GlcNAc	In vitro: cell-permeable, effective inhibition of OGT	(102)	
OGT	5SGlcNAc	Analog of UDP-GlcNAc	In vitro: reduces O-GlcNAc level	(102)	
OGT	5SGlcNHex	Analog of UDP-GlcNAc	In vitro: inhibits OGT
In vivo: effective at lowering the tissue O-GlcNAc level	(103)	
OGT	Compound 2	Analog of UDP-GlcNAc	In vitro: cell-permeable, irreversibly inhibits OGT	(104)	
OGT	L01		In vitro: reduces O-GlcNAc level with low toxicity
In vivo: effectively inhibits Ogt activity in zebrafish	(105)	
OGT	OSMI-1	Hinge interactions with OGT Ala896	In vitro: reduces O-GlcNAc level	(106)	
OGT	OSMI-3, OSMI-4	Hinge interactions with OGT Ala896	In vitro: reduces O-GlcNAc level	(107)	
OGA	α-GlcNAc thiolsulfonate	Analog of UDP-GlcNAc	In vitro: selectively inhibits short OGA	(108)	
OGA	GlcNAcstatins	Analog of GlcNAc	In vitro: high potency and selectivity	(109, 110)	
OGA	NAG-thiazoline	Transition state analog	In vitro: greater selectivity than PUGNAc	(111)	
OGA	PUGNAc	Transition state analog, cell-permeable inhibitor	In vitro: limited aqueous solubility, low specificity	(112)	
OGA	Streptozotocin	Transition state analog	In vitro: major off-target effects	(113)	
OGA	NButGT	Transition state analog	In vitro: less potent, higher selectivity	(114)	
OGA	Thiamet G	Derivative of NButGT	In vitro: restores O-GlcNAcylation levels with high stability and good water solubility
In vivo: orally available	(114)	
OGA	MK-8719	5-Difluoromethyl derivate of thiamet-G	In vivo: increased O-protein levels in PBMCs and brain tissue.	(115)	
OGA	Formulaic Ia (LY3372689)		In vivo: plasma-concentration-related increase in brain OGA occupancy	(116)	
OGA	ASN90		In vivo: elevates the O-GlcNAcylation of brain proteins	(117)	
HBP	Azaserine	Decreases HBP flux by inhibiting GFAT	In vitro: reduces HBP flux, but lacks specificity
In vivo: in clinical trials	(118)	
HBP	6-Diazo-5-oxo-L-norleucine (DON)	Decreases HBP flux by inhibiting GFAT	In vitro: reduces HBP flux, but lacks specificity
In vivo: in clinical trials	(119)	
GFAT, glutamine fructose-6-phosphate amidotransferase.

Although O-GlcNAcylation plays an important role in tumors, its physiological function in maintaining the cellular homeostasis of normal tissues is indispensable. Whole-body depletion of Ogt or Oga leads to a lethal phenotype (86, 94, 95), which undermines the potential toxicity of inhibitors of OGA or OGT that disrupt the universal O-GlcNAcylation of different protein substrates. Therefore, approaches that specifically modulate the O-GlcNAcylation of a tumor-driven target protein are urgently needed for targeted cancer therapy. CIP is an emerging field that has been recently adopted to manipulate protein‒protein interactions (19), especially for modulating specific PTMs of disease-causing proteins, including ubiquitination, phosphorylation, and acetylation. The best known CIP examples are PROTACs, while molecule glues that induce protein‒protein interactions have a longer history, for example, FK506 and rapamycin (20).

CIPs that modulate the PTM of a protein usually consist of three distinct functional moieties, namely, two ligands that recruit the protein substrate and the PTM enzyme and a linker that connects the two parts (20). Notably, to enable the functional modification of the PTM of the protein substrate, the ligand of the enzyme should bind specifically to the enzyme but not disrupt its enzymatic activity. In addition to small molecules, available ligands for recruiting enzymes in CIP design include DNA/RNA nucleotides and peptides, and ligands of substrate proteins could also be small molecules or antibodies. For example, DNA oligomer-based ligands have been used in PROTAC design to recruit DNA-binding proteins, such as transcription factors and telomeres (120, 121, 122, 123). Due to advances in cyclic peptide and stapled peptide technology, which resolve the stability issue of peptide drugs, peptide-based ligands constitute another class of ligands that can be used in CIP design, and several successful peptide-based PROTAC examples have recently been reported to degrade undruggable targets, such as AR-v7, which escapes the inhibition of canonical AR inhibitors (124). For O-GlcNAcylation, RNA aptamer and nanobody technologies have been adopted to design CIPs (125, 126, 127) (Fig. 6).Figure 6 Chemical-induced proximity method for targeting protein O-GlcNAcylation.A, strategy for targeted O-GlcNAc induction using a proximity-directed nanobody-OGT. B, design of a nanobody-directed split OGA for selective O-GlcNAc removal from proteins. C, concept and target engagement of OGTAC technology. D, dual-specific aptamers enhance the O-GlcNAcylation of target proteins. POI: protein of interest. G: O-GlcNAcylation. OGT, O-GlcNAc transferase; O-GlcNAcylation, O-linked N-acetylglucosaminylation; OGTAC, O-GlcNAcylation targeting chimera.

The Woo group developed nanobody-based OGT (125) in 2020 and nanobody-based splitOGA methods in 2021 to add or remove O-GlcNAcylation from a specific target protein, respectively (126). In the nanobody-based OGT design, a nanobody of protein of interest (POI) is fused to OGT, thus recruiting OGT to be in proximity and selectively transfer O-GlcNAc onto POIs, such as JunB, c-Jun, Nup62, and α-synuclein (Fig. 6A) (125). In the nanobody-based splitOGA design, the OGA protein is split into two parts: a larger part contains the main catalytic domain but has reduced deglycosylase activity without adding a smaller part that is fused with the nanobody. The prototype nanobody-based splitOGA has been proven to be efficient in erasing the O-GlcNAc modification from POIs, such as SP1, c-Jun, c-Fos, JunB, c-Jun, and Nup62 (Fig. 6B) (126). Using a tag system, in 2024, the Ng group reported O-GlcNAcylation targeting chimeras (OGTACs), which are bifunctional small molecules that add O-GlcNAcylation to POIs in cells (128). In this design, they use ectopic FKBP12F36V-fused OGT as the enzyme and ectopic HaloTag-fused POIs as protein substrates, which illustrates that OGTACs can specifically mediate the O-GlcNAcylation of POIs, including BRD4, CK2α, and EZH2 in cells (Fig. 6C) (128). Given that the lack of O-GlcNAcylation mimics the amino acid mutation of the residue for this PTM, previous studies on O-GlcNAcylation have focused mainly on the loss-of-function mutation of serine/threonine-to-alanine (S/T-to-A), which cannot be used to dissect the function of O-GlcNAcylation from other PTMs, such as phosphorylation, on the same residue. Thus, the dual-specificity RNA aptamer provides a powerful tool and paves a new path to study the function of O-GlcNAcylation of specific substrate proteins without affecting other substrates (Fig. 6D) (127). Although the relative efficiency and specificity of these chemical engineering methods have been proven, a noticeable drawback is that an ectopically fused enzyme and/or a fused POI needs to be introduced into cells, which is not tolerable in clinical practice, thus restricting their usage only as a research tool in the laboratory.

More recently, using an high-throughput screening method, the Hart group reported the first RNA aptamer that recruits OGT, on the basis of which they linked it to another RNA aptamer of β-catenin, yielding a dual RNA aptamer to bridge endogenous OGT and β-catenin, thus specifically catalyzing the O-GlcNAcylation of β-catenin (127). Furthermore, the aptamer could be developed into an inducible expression system, making it more feasible and controllable in practice (127). Using the dual-specificity RNA aptamer, the biological function of O-GlcNAcylation of β-catenin has been revealed to disrupt the interaction between β-catenin and other proteins and to recruit EZH2 to the gene promoter to remodel the transcriptome (127). Given that OGT and POIs are endogenous proteins and that recent advances in the mRNA vaccine field have provided solutions to resolve the stability and delivery issues of RNA medicine, such dual-specificity RNA aptamer methods might be translated into clinical use in the near future.

Conclusions

O-GlcNAcylation is a dynamic and reversible PTM of proteins that is involved in almost all cell biological processes and has complex functions in cancer. Many proteins, such as metabolic enzymes, cell signal transduction molecules, and gene expression regulators, are O-GlcNAcylated in response to high glucose or other stimuli to either protect them from degradation or maintain/inhibit their original biological functions in a context-dependent manner. Genetically engineered mouse models, including whole-body or tissue-specific depletion of Ogt or Oga, reveal the pivotal physiological functions of O-GlcNAcylation in maintaining cellular homeostasis. Small-molecule inhibitors of OGT or OGA have been developed to combat various types of cancers both in vitro and in vivo. Therefore, drugs that grossly inhibit global O-GlcNAcylation might have serious side effects, thus highlighting the need for alternative approaches to manipulate the O-GlcNAcylation of specific targets accurately without disturbing the functions of other O-GlcNAcylation substrates. To date, several CIPs, including OGTACs and RNA aptamers, have been reported to be able to precisely modulate the O-GlcNAcylation of POIs, suggesting that CIPs might be powerful tools for either studying the biological function of O-GlcNAcylation or serving as therapeutic options in translational studies of human cancers. However, their efficiency and specificity have only been tested in cellular experiments, and further in-depth in vivo studies, such as those using genetically engineered mouse model or patient-derived xenograft models, are needed to evaluate their translational potential in the future.

Conflict of interest

W.W. is a co-founder and consultant for the ReKindle Therapeutics. Other authors declare that they have no conflicts of interest with the contents of this article.

Author contributions

D. Z., Y. Q., H. I., J. L., and W. W. writing–review and editing; D. Z., Y. Q., and H. I. writing–original draft; D. Z. and Y. Q. resources; J. L. and W. W. conceptualization.

Funding and additional information

This work was supported by the 10.13039/100000002 NIH grants (R35CA253027 to W. W.) and 10.13039/501100012166 National Key Research and Development Program of China (2023YFC1404100 to J. L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We apologize that due to space limitations, not all related studies are cited and discussed in this review.
==== Refs
References

1 Torres C.R. Hart G.W. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc J. Biol. Chem. 259 1984 3308 3317 6421821
2 Haltiwanger R.S. Blomberg M.A. Hart G.W. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase J. Biol. Chem. 267 1992 9005 9013 1533623
3 Gao Y. Wells L. Comer F.I. Parker G.J. Hart G.W. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain J. Biol. Chem. 276 2001 9838 9845 11148210
4 Toleman C.A. Schumacher M.A. Yu S.-H. Zeng W. Cox N.J. Smith T.J. Structural basis of O-GlcNAc recognition by mammalian 14-3-3 proteins Proc. Natl. Acad. Sci. U. S. A. 115 2018 5956 5961 29784830
5 Le Minh G. Esquea E.M. Young R.G. Huang J. Reginato M.J. On a sugar high: role of O-GlcNAcylation in cancer J. Biol. Chem. 299 2023 105344 37838167
6 Parker M.P. Peterson K.R. Slawson C. O-GlcNAcylation and O-GlcNAc cycling regulate gene transcription: emerging roles in cancer Cancers 13 2021 998 33673630
7 Dehennaut V. Leprince D. Lefebvre T. O-GlcNAcylation, an epigenetic mark. Focus on the histone code, TET family proteins, and polycomb group proteins Front. Endocrinol. 5 2014 155
8 Li X. Gong W. Wang H. Li T. Attri K.S. Lewis R.E. O-GlcNAc transferase suppresses inflammation and necroptosis by targeting receptor-interacting serine/threonine-protein kinase 3 Immunity 50 2019 576 590 30770249
9 Dias W.B. Cheung W.D. Hart G.W. O-GlcNAcylation of kinases Biochem. Biophys. Res. Commun. 422 2012 224 228 22564745
10 van der Laarse S.A.M. Leney A.C. Heck A.J.R. Crosstalk between phosphorylation and O-GlcNAcylation: friend or foe FEBS J. 285 2018 3152 3167 29717537
11 Ma J. Hou C. Wu C. Demystifying the O-GlcNAc code: a systems view Chem. Rev. 122 2022 15822 15864 35302357
12 He X.-F. Hu X. Wen G.-J. Wang Z. Lin W.-J. O-GlcNAcylation in cancer development and immunotherapy Cancer Lett. 566 2023 216258 37279852
13 Hou C. Zhu W. Pei H. Systematic pan-cancer analysis reveals OGT and OGA as potential biomarkers for tumor microenvironment and therapeutic responses Genes Dis. 11 2024 101089 38362042
14 Ferrer C.M. Sodi V.L. Reginato M.J. O-GIcNAcylation in cancer biology: linking metabolism and signaling J. Mol. Biol. 428 2016 3282 3294 27343361
15 Chen L. Hu M. Chen L. Peng Y. Zhang C. Wang X. Targeting O-GlcNAcylation in cancer therapeutic resistance: the sugar Saga continues Cancer Lett. 588 2024 216742 38401884
16 Chen Y.-F. Zhu J.-J. Li J. Ye X.-S. O-GlcNAcylation increases PYGL activity by promoting phosphorylation Glycobiology 32 2022 101 109 34939084
17 Ruan H.-B. Nie Y. Yang X. Regulation of protein degradation by O-GlcNAcylation: crosstalk with ubiquitination Mol. Cell Proteomics 12 2013 3489 3497 23824911
18 Elbatrawy A.A. Kim E.J. Nam G. O-GlcNAcase: emerging mechanism, substrate recognition and small-molecule inhibitors Chemmedchem 15 2020 1244 1257 32496638
19 Peng Y. Liu J. Inuzuka H. Wei W. Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy J. Biol. Chem. 299 2023 104572 36870680
20 Stanton B.Z. Chory E.J. Crabtree G.R. Chemically induced proximity in biology and medicine Science 359 2018 eaao5902 29590011
21 Gao X. Burris III H.A. Vuky J. Dreicer R. Sartor A.O. Sternberg C.N. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 40 2022 10.1200/JCO.2022.40.6_suppl.017
22 Hamilton E. Vahdat L. Han H.S. Ranciato J. Gedrich R. Keung C.F. First-in-human safety and activity of ARV-471, a novel PROTAC estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer Cancer Res. 82 2022 10.1158/1538-7445.SABCS21-PD13-08
23 Kim K. Yoo H.C. Kim B.G. Kim S. Sung Y. Yoon I. O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine Nat. Commun. 13 2022 2904 35614056
24 Itkonen H.M. Gorad S.S. Duveau D.Y. Martin S.E.S. Barkovskaya A. Bathen T.F. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism Oncotarget 7 2016 12464 12476 26824323
25 Yi W. Clark P.M. Mason D.E. Keenan M.C. Hill C. Goddard W.A. III Phosphofructokinase 1 glycosylation regulates cell growth and metabolism Science 337 2012 975 980 22923583
26 Rao X. Duan X. Mao W. Li X. Li Z. Li Q. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth Nat. Commun. 6 2015 8468 26399441
27 Nie H. Ju H. Fan J. Shi X. Cheng Y. Cang X. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth Nat. Commun. 11 2020 36 31911580
28 Wang Y. Liu J. Jin X. Zhang D. Li D. Hao F. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect Proc. Natl. Acad. Sci. U. S. A. 114 2017 13732 13737 29229835
29 Zhou Z. Zheng X. Zhao J. Yuan A. Lv Z. Shao G. ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer Oncogene 43 2024 1769 1778 38632437
30 Wang T. Yu Q. Li J. Hu B. Zhao Q. Ma C. O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency Nat. Cell Biol. 19 2017 833 843 28628081
31 Wong Y.-K. Wang J. Lim T.K. Lin Q. Yap C.T. Shen H.-M. O-GlcNAcylation promotes fatty acid synthase activity under nutritional stress as a pro-survival mechanism in cancer cells Proteomics 22 2022 e2100175 35083852
32 Tan W. Jiang P. Zhang W. Hu Z. Lin S. Chen L. Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation Mol. Cell 81 2021 1890 1904 33657401
33 Bacigalupa Z. Smith M.D. Ferrer C.M. D'Agostino L. Trefely S. Snyder N. O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation Mol. Biol. Cell 28 2017 2122 2136
34 Butler M. van der Meer L.T. van Leeuwen F.N. Amino acid depletion therapies: starving cancer cells to death Trends Endocrinol. Metab. 32 2021 367 381 33795176
35 Zhu Q. Zhou H. Wu L. Lai Z. Geng D. Yang W. O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1 Nat. Chem. Biol. 18 2022 1087 1095 35879546
36 Chen L. Zhou Q. Zhang P. Tan W. Li Y. Xu Z. Direct stimulation of de novo nucleotide synthesis by O-GlcNAcylation Nat. Chem. Biol. 20 2024 19 29 37308732
37 Xu C. Pan X. Wang D. Guan Y. Yang W. Chen X. O-GlcNAcylation of Raptor transduces glucose signals to mTORC1 Mol. Cell 83 2023 3027 3040 37541260
38 Li X. Yue X. Sepulveda H. Burt R.A. Scott D.A. Carr S.A. OGT controls mammalian cell viability by regulating the proteasome/mTOR/mitochondrial axis Proc. Natl. Acad. Sci. U. S. A. 120 2023 e2218332120
39 Park S. Pak J. Jang I. Cho J.W. Inhibition of mTOR affects protein stability of OGT Biochem. Biophys. Res. Commun. 453 2014 208 212 24858682
40 Sodi V.L. Khaku S. Krutilina R. Schwab L.P. Vocadlo D.J. Seagroves T.N. mTOR/MYC Axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer Mol. Cancer Res. 13 2015 923 933 25636967
41 Bullen J.W. Balsbaugh J.L. Chanda D. Shabanowitz J. Hunt D.F. Neumann D. Cross-talk between two essential nutrient-sensitive enzymes O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK) J. Biol. Chem. 289 2014 10592 10606 24563466
42 Xu Q. Yang C. Du Y. Chen Y. Liu H. Deng M. AMPK regulates histone H2B O-GlcNAcylation Nucleic Acids Res. 42 2014 5594 5604 24692660
43 Gelinas R. Mailleux F. Dontaine J. Bultot L. Demeulder B. Ginion A. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation Nat. Commun. 9 2018 519 29410432
44 Whelan S.A. Dias W.B. Thiruneelakantapillai L. Lane M.D. Hart G.W. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked β-N-acetylglucosamine in 3T3-L1 adipocytes J. Biol. Chem. 285 2010 5204 5211 20018868
45 Yang X. Ongusaha P.P. Miles P.D. Havstad J.C. Zhang F. So W.V. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance Nature 451 2008 964 969 18288188
46 Ruan H.-B. Ma Y. Torres S. Zhang B. Feriod C. Heck R.M. Calcium-dependent O-GlcNAc signaling drives liver autophagy in adaptation to starvation Genes Dev. 31 2017 1655 1665 28903979
47 Jeong W. Kim S. Lee U. Zhong Z.A. Savitsky M. Kwon H. LDLreceptor-related proteinLRP6 senses nutrient levels and regulates Hippo signaling EMBO Rep. 21 2020 e50103 32767654
48 Kim E. Kang J.G. Kang M.J. Park J.H. Kim Y.J. Kweon T.H. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity Proc. Natl. Acad. Sci. U. S. A. 117 2020 14259 14269 32513743
49 Zhang X. Qiao Y. Wu Q. Chen Y. Zou S. Liu X. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis Nat. Commun. 8 2017 15280 28474680
50 Olivier-Van Stichelen S. Dehennaut V. Buzy A. Zachayus J.-L. Guinez C. Mir A.-M. O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41 FASEB J. 28 2014 3325 3338 24744147
51 Hua Q. Zhang B. Xu G. Wang L. Wang H. Lin Z. CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of β-catenin Oncogene 40 2021 6443 6455 34608265
52 Li T. Li X. Attri K.S. Liu C. Li L. Herring L.E. O-GlcNAc transferase links glucose metabolism to MAVS-mediated antiviral innate immunity Cell Host Microbe 24 2018 791 803 30543776
53 Ma Z. Vocadlo D.J. Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells J. Biol. Chem. 288 2013 15121 15130 23592772
54 Kawauchi K. Araki K. Tobiume K. Tanaka N. Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification Proc. Natl. Acad. Sci. U. S. A. 106 2009 3431 3436 19202066
55 Motolani A. Martin M. Wang B. Jiang G. Alipourgivi F. Huang X. Critical role of novel O-GlcNAcylation of S550 and S551 on the p65 subunit of NF-κB in pancreatic cancer Cancers 15 2023 4742 37835439
56 Ali A. Kim S.H. Kim M.J. Choi M.Y. Kang S.S. Cho G.J. O-GlcNAcylation of NF-κB promotes lung metastasis of cervical cancer cells via upregulation of CXCR4 expression Mol. Cells 40 2017 476 484 28681591
57 Shin H. Leung A. Costello K.R. Senapati P. Kato H. Moore R.E. Inhibition of DNMT1 methyltransferase activity via glucose-regulated O-GlcNAcylation alters the epigenome Elife 12 2023 e85595 37470704
58 Fujiki R. Hashiba W. Sekine H. Yokoyama A. Chikanishi T. Ito S. GlcNAcylation of histone H2B facilitates its monoubiquitination Nature 480 2011 557 560 22121020
59 Hirosawa M. Hayakawa K. Yoneda C. Arai D. Shiota H. Suzuki T. Novel O-GlcNAcylation on Ser40 of canonical H2A isoforms specific to viviparity Sci. Rep. 6 2016 31785 27615797
60 Hayakawa K. Hirosawa M. Tani R. Yoneda C. Tanaka S. Shiota K. H2A O-GlcNAcylation at serine 40 functions genomic protection in association with acetylated H2AZ or γH2AX Epigenet. Chromatin 10 2017 51
61 Chu C.-S. Lo P.-W. Yeh Y.-H. Hsu P.-H. Peng S.-H. Teng Y.-C. O-GlcNAcylation regulates EZH2 protein stability and function Proc. Natl. Acad. Sci. U. S. A. 111 2014 1355 1360 24474760
62 He X. Li Y. Chen Q. Zheng L. Lou J. Lin C. O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGγ interaction Cell Death Differ. 29 2022 1970 1981 35422493
63 Liu Y. Yu K. Zhang K. Niu M. Chen Q. Liu Y. O-GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance EMBO Rep. 24 2023 e56458 37249035
64 Yang X.Y. Zhang F.X. Kudlow J.E. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression Cell 110 2002 69 80 12150998
65 Lewis B.A. The role of O-GlcNAcylation in RNA polymerase II transcription J. Biol. Chem. 300 2024 105705 38311176
66 Chou T.Y. Dang C.V. Hart G.W. Glycosylation of the C-MYC transactivation domain Proc. Natl. Acad. Sci. U. S. A. 92 1995 4417 4421 7753821
67 Chou T.Y. Hart G.W. Dang C.V. C-MYC IS glycosylated at threonine-58, a known phosphorylation site and a mutational hot-spot in lymphomas J. Biol. Chem. 270 1995 18961 18965 7642555
68 Shang M. Yang H. Yang R. Chen T. Fu Y. Li Y. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation Nat. Commun. 12 2021 1940 33782411
69 Ferrer C.M. Lynch T.P. Sodi V.L. Falcone J.N. Schwab L.P. Peacock D.L. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway Mol. Cell 54 2014 820 831 24857547
70 Yang W.H. Kim J.E. Nam H.W. Ju J.W. Kim H.S. Kim Y.S. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability Nat. Cell Biol. 8 2006 1074 1083 16964247
71 Su Y. Luo Y. Zhang P. Lin H. Pu W. Zhang H. Glucose-induced CRL4COP1-p53 axis amplifies glycometabolism to drive tumorigenesis Mol. Cell 83 2023 2316 2331 37390815
72 Sodi V.L. Bacigalupa Z.A. Ferrer C.M. Lee J.V. Gocal W.A. Mukhopadhyay D. Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation Oncogene 37 2018 924 934 29059153
73 Jhu J.-W. Yan J.-B. Lin Z.-H. Lin S.-C. Peng I.C. SREBP1-Induced glutamine synthetase triggers a feedforward loop to upregulate SREBP1 through Sp1 O-GlcNAcylation and augments lipid droplet formation in cancer cells Int. J. Mol. Sci. 22 2021 9814 34575972
74 Hardiville S. Banerjee P.S. Alpergin E.S.S. Smith D.M. Han G. Ma J. TATA-box binding protein O-GlcNAcylation at T114 regulates formation of the B-TFIID complex and is critical for metabolic gene regulation Mol. Cell 77 2020 1143 1152 31866147
75 Cai Y. Chen M. Gong Y. Tang G. Shu Z. Chen J. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor Clin. Transl. Med. 14 2024 e1531 38214432
76 Liu Y. Yu K. Kong X. Zhang K. Wang L. Zhang N. FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer Sci. Adv. 9 2023 eadg7112 37595040
77 Ma Z. Chalkley R.J. Vosseller K. Hyper-O-GlcNAcylation activates nuclear factor κ-light-chainenhancer of activated B cells (NF-κB) signaling through interplay with phosphorylation and acetylation J. Biol. Chem. 292 2017 9150 9163 28416608
78 Chen Y. Wan R. Zou Z. Lao L. Shao G. Zheng Y. O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins Nat. Cell Biol. 25 2023 1676 1690 37945829
79 Li X. Zhu Q. Shi X. Cheng Y. Li X. Xu H. O-GIcNAcylation of core components of the translation initiation machinery regulates protein synthesis Proc. Natl. Acad. Sci. U. S. A. 116 2019 7857 7866 30940748
80 Melero-Fernandez de Mera R.M. Arasu U.T. Karna R. Oikari S. Rilla K. Vigetti D. Effects of mutations in the post-translational modification sites on the trafficking of hyaluronan synthase 2 (HAS2) Matrix Biol. 80 2019 85 103 30394292
81 Yao D. Taguchi T. Matsumura T. Pestell R. Edelstein D. Giardino I. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A J. Biol. Chem. 282 2007 31038 31045 17670746
82 Lynch T.P. Ferrer C.M. Jackson S.R. Shahriari K.S. Vosseller K. Reginato M.J. Critical role of O-linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis J. Biol. Chem. 287 2012 11070 11081 22275356
83 Li X. Peng X. Zhang C. Bai X. Li Y. Chen G. Bladder cancer-derived small extracellular vesicles promote tumor angiogenesis by inducing HBP-related metabolic reprogramming and SerRS O-GlcNAcylation in endothelial cells Adv. Sci. 9 2022 e2202993
84 Zhu Q. Wang H. Chai S. Xu L. Lin B. Yi W. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation Proc. Natl. Acad. Sci. U. S. A. 120 2023 e2216796120
85 Swamy M. Pathak S. Grzes K.M. Damerow S. Sinclair L.V. van Aalten D.M.F. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy Nat. Immunol. 17 2016 712 720 27111141
86 Shafi R. Lyer S.P.N. Ellies L.G. O'Donnell N. Marek K.W. Chui D. The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny Proc. Natl. Acad. Sci. U. S. A. 97 2000 5735 5739 10801981
87 Ida S. Morino K. Sekine O. Ohashi N. Kume S. Chano T. Diverse metabolic effects of O-GlcNAcylation in the pancreas but limited effects in insulin-sensitive organs in mice Diabetologia 60 2017 1761 1769 28642969
88 Shi H. Munk A. Nielsen T.S. Daughtry M.R. Larsson L. Li S. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity Mol. Metab. 11 2018 160 177 29525407
89 O'Donnell N. Zachara N.E. Hart G.W. Marth J.D. Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability Mol. Cell Biol. 24 2004 1680 1690 14749383
90 Wu J.L. Chiang M.F. Hsu P.H. Tsai D.Y. Hung K.H. Wang Y.H. O-GlcNAcylation is required for B cell homeostasis and antibody responses Nat. Commun. 8 2017 1854 29187734
91 Wang Q. Fang P. He R. Li M. Yu H. Zhou L. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5 Sci. Adv. 6 2020 eaaz7086
92 Chen L. Li Y. Song Z. Xue S. Liu F. Chang X. O-GlcNAcylation promotes cerebellum development and medulloblastoma oncogenesis via SHH signaling Proc. Natl. Acad. Sci. U. S. A. 119 2022 e2202821119
93 Duan F. Wu H. Jia D. Wu W. Ren S. Wang L. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis J. Hepatol. 68 2018 1191 1202 29454068
94 Yang Y.R. Song M. Lee H. Jeon Y. Choi E.J. Jang H.J. O-GlcNAcase is essential for embryonic development and maintenance of genomic stability Aging Cell 11 2012 439 448 22314054
95 Keembiyehetty C. Love D.C. Harwood K.R. Gavrilova O. Comly M.E. Hanover J.A. Conditional knock-out reveals a requirement for O-linked N-Acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis J. Biol. Chem. 290 2015 7097 7113 25596529
96 Muha V. Authier F. Szoke-Kovacs Z. Johnson S. Gallagher J. McNeilly A. Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis J. Biol. Chem. 296 2021 100439
97 Yang Y.R. Jang H.J. Yoon S. Lee Y.H. Nam D. Kim I.S. OGA heterozygosity suppresses intestinal tumorigenesis in Apc(min/+) mice Oncogenesis 3 2014 e109 25000257
98 Pratt M.R. Vocadlo D.J. Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases J. Biol. Chem. 299 2023 105411
99 Konrad R.J. Zhang F.X. Hale J.E. Knierman M.D. Becker G.W. Kudlow J.E. Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase Biochem. Biophys. Res. Commun. 293 2002 207 212 12054585
100 Chen H. Lou Y. Lin S. Tan X. Zheng Y. Yu H. Formononetin, a bioactive isoflavonoid constituent from Astragalus membranaceus (Fisch.) Bunge, ameliorates type 1 diabetes mellitus via activation of Keap1/Nrf2 signaling pathway: an integrated study supported by network pharmacology and experimental validation J. Ethnopharmacol. 322 2024 117576
101 Pantaleon M. Tan H.Y. Kafer G.R. Kaye P.L. Toxic effects of hyperglycemia are mediated by the hexosamine signaling pathway and O-linked glycosylation in early mouse embryos Biol. Reprod. 82 2010 751 758 20032283
102 Gloster T.M. Zandberg W.F. Heinonen J.E. Shen D.L. Deng L. Vocadlo D.J. Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells Nat. Chem. Biol. 7 2011 174 181 21258330
103 Liu T.-W. Zandberg W.F. Gloster T.M. Deng L. Murray K.D. Shan X. Metabolic inhibitors of O-GlcNAc transferase that act in vivo implicate decreased O-GlcNAc levels in leptin-mediated nutrient sensing Angew. Chem. Int. Ed. Engl. 57 2018 7644 7648 29756380
104 Jiang J. Lazarus M.B. Pasquina L. Sliz P. Walker S. A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase Nat. Chem. Biol. 8 2012 72 77
105 Liu Y. Ren Y. Cao Y. Huang H. Wu Q. Li W. Discovery of a low toxicity O-GlcNAc transferase (OGT) inhibitor by structure-based virtual screening of natural products Sci. Rep. 7 2017 12334 28951553
106 Ortiz-Meoz R.F. Jiang J. Lazarus M.B. Orman M. Janetzko J. Fan C. A small molecule that inhibits OGT activity in cells Acs Chem. Biol. 10 2015 1392 1397 25751766
107 Martin S.E.S. Tan Z.-W. Itkonen H.M. Duveau D.Y. Paulo J.A. Janetzko J. Structure-based evolution of low nanomolar O-GlcNAc transferase inhibitors J. Am. Chem. Soc. 140 2018 13542 13545 30285435
108 Kim E.J. Amorelli B. Abdo M. Thomas C.J. Love D.C. Knapp S. Distinctive inhibition of O-GlcNAcase isoforms by an α-GlcNAc thiolsulfonate J. Am. Chem. Soc. 129 2007 14854 14855 17994748
109 Dorfmueller H.C. Borodkin V.S. Schimpl M. Shepherd S.M. Shpiro N.A. van Aalten D.M.F. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels J. Am. Chem. Soc. 128 2006 16484 16485 17177381
110 Dorfmueller H.C. Borodkin V.S. Schimpl M. van Aalten D.M.F. GIcNAcstatins are nanomolar inhibitors of human O-GIcNAcase inducing cellular hyper-O-GIcNAcylation Biochem. J. 420 2009 221 227 19275764
111 Whitworth G.E. Macauley M.S. Stubbs K.A. Dennis R.J. Taylor E.J. Davies G.J. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise J. Am. Chem. Soc. 129 2007 635 644 17227027
112 Whitworth G.E. Stubbs K.A. Macauley M.S. Dennis R.J. Davies G.J. Greig I.R. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise Biochem. Cell Biol. Biochimie Biologie Cellulaire 86 2008 201 202
113 Toleman C. Paterson A.J. Shin R. Kudlow J.E. Streptozotocin inhibits O-GlcNAcase via the production of a transition state analog Biochem. Biophys. Res. Commun. 340 2006 526 534 16376298
114 Macauley M.S. Vocadlo D.J. Increasing O-GlcNAc levels: an overview of small-molecule inhibitors of O-GlcNAcase Biochim. Biophys. Acta 1800 2010 107 121 19664691
115 Selnick H.G. Hess J.F. Tang C. Liu K. Schachter J.B. Ballard J.E. Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for tauopathies J. Med. Chem. 62 2019 10062 10097 31487175
116 Shcherbinin S. Kielbasa W. Dubois S. Lowe S.L. Phipps K.M. Tseng J. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: translation from rat to human: neuroimaging/evaluating treatments Alzheimer's Demen. 16 2020 e040558
117 Permanne B. Sand A. Ousson S. Nény M. Hantson J. Schubert R. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies ACS Chem. Neurosci. 13 2022 1296 1314 35357812
118 Marshall S. Bacote V. Traxinger R.R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance J. Biol. Chem. 266 1991 4706 4712 2002019
119 Catane R. Vonhoff D.D. Glaubiger D.L. Muggia F.M. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity Cancer Treat. Rep. 63 1979 1033 1038 380801
120 Liu J. Chen H. Kaniskan H.U. Xie L. Chen X. Jin J. TF-PROTACs enable targeted degradation of transcription factors J. Am. Chem. Soc. 143 2021 8902 8910 34100597
121 Wang Z. Liu J. Chen H. Qiu X. Xie L. Kaniskan H.U. Telomere targeting chimera enables targeted destruction of telomeric repeat-binding factor proteins J. Am. Chem. Soc. 145 2023 10872 10879 37141574
122 Samarasinghe K.T.G. Jaime-Figueroa S. Burgess M. Nalawansha D.A. Dai K. Hu Z. Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras Cell Chem. Biol. 28 2021 648 661 33836141
123 Samarasinghe K.T.G. An E. Genuth M.A. Chu L. Holley S.A. Crews C.M. OligoTRAFTACs: a generalizable method for transcription factor degradation Rsc Chem. Biol. 3 2022 1144 1153 36128504
124 Ma B. Fan Y. Zhang D. Wei Y. Jian Y. Liu D. De novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy Adv. Sci. 9 2022 e2201859
125 Ramirez D.H. Aonbangkhen C. Wu H.-Y. Naftaly J.A. Tang S. O'Meara T.R. Engineering a proximity-directed O-GlcNAc transferase for selective protein O-GlcNAcylation in cells Acs Chem. Biol. 15 2020 1059 1066 32119511
126 Ge Y. Ramirez D.H. Yang B. D'Souza A.K. Aonbangkhen C. Wong S. Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase Nat. Chem. Biol. 17 2021 593 600 33686291
127 Zhu Y. Hart G.W. Dual-specificity RNA aptamers enable manipulation of target-specific O-GlcNAcylation and unveil functions of O-GlcNAc on β-catenin Cell 186 2023 428 445 36626902
128 Ma B. Khan K.S. Xu T. Amada J.X. Guo Z. Huang Y. Targeted protein O-GlcNAcylation using bifunctional small molecules J. Am. Chem. Soc. 146 2024 9779 9789 38561350
